{"disease":{"id":"infectious-disease","name":"infectious disease"},"drugs":{"marketed":[{"drug_id":"cefiderocol","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fetroja","generic_name":"CEFIDEROCOL","company_name":"Shionogi","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":"300","mechanism":"Fetroja works by binding to penicillin-binding proteins on bacterial cell walls, inhibiting cell wall synthesis and ultimately leading to bacterial cell death."},{"drug_id":"mezlocillin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MEZLOCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"Interleukin-8","drug_class":"mezlocillin","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"fusidic-acid","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"fusidic-acid","indication_name":"Pneumococcal infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"fusidic-acid","indication_name":"Staphylococcal infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"fusidic-acid","indication_name":"Streptococcal infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"fusidic-acid","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"furazidin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Furagin","generic_name":"furazidin","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Furagin works by inhibiting bacterial growth and replication, specifically targeting the bacterial enzyme responsible for DNA synthesis."},{"drug_id":"gentamicin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"erythromycin-ethyl-succinate","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eryped","generic_name":"Erythromycin ethyl succinate","company_name":"Arbor Pharms Llc","drug_phase":"marketed","molecular_target":"","drug_class":"Macrolide","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"erythromycin-ethyl-succinate","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eryped","generic_name":"Erythromycin ethyl succinate","company_name":"Arbor Pharms Llc","drug_phase":"marketed","molecular_target":"","drug_class":"Macrolide","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"doripenem","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doribax","generic_name":"DORIPENEM","company_name":"Shionogi","drug_phase":"marketed","molecular_target":"","drug_class":"Penem Antibacterial","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"tigecycline","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tygacil","generic_name":"TIGECYCLINE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"30S ribosomal subunit","drug_class":"Tetracycline-class Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Tygacil works by binding to the 30S ribosomal subunit of bacteria, preventing the aminoacyl-tRNA from binding and thereby inhibiting protein synthesis."},{"drug_id":"cefradine","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefradex","generic_name":"cefradine","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"cefradine","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"cefapirin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefaprin","generic_name":"cefapirin","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"cefapirin","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"amoxycillin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxycillin","company_name":"King George's Medical University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"sodium-phosphate-monobasic-monohydrate","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Osmoprep","generic_name":"sodium phosphate, monobasic, monohydrate","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Calculi Dissolution Agent [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"benzylpenicillin","indication_name":"Streptococcal infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Penicillin G Potassium In Plastic Container","generic_name":"Benzylpenicillin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"nafcillin-sodium","indication_name":"Staphylococcal infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nallpen In Plastic Container","generic_name":"NAFCILLIN SODIUM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"clindamycin-phosphate","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cleocin T","generic_name":"CLINDAMYCIN PHOSPHATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Lincosamide Antibacterial","quality_score":51,"revenue":null,"mechanism":"Cleocin T works by inhibiting protein synthesis in bacteria, preventing them from producing essential proteins and ultimately leading to cell death."},{"drug_id":"vancomycin","indication_name":"Staphylococcal infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vancocin","generic_name":"vancomycin","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor, D-alanyl-D-alanine dipeptidase, UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"cefepime","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maxipime","generic_name":"CEFEPIME","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":59,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug."},{"drug_id":"eravacycline-dihydrochloride","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE DIHYDROCHLORIDE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Xerava works by binding to the bacterial ribosome, preventing the synthesis of essential proteins necessary for bacterial survival."},{"drug_id":"nafcillin","indication_name":"Staphylococcal infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nallpen In Plastic Container","generic_name":"NAFCILLIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefotaxime","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claforan","generic_name":"CEFOTAXIME","company_name":"Sterimax","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"ampicillin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"ampicillin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"clindamycin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cleocin","generic_name":"clindamycin","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"50S ribosomal protein L10","drug_class":"Lincosamide antibiotic","quality_score":56,"revenue":null,"mechanism":"Lincosamide antibiotic that binds the 50S ribosomal subunit, inhibiting bacterial protein synthesis with excellent anaerobic coverage."},{"drug_id":"moxifloxacin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelox","generic_name":"moxifloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"Fluoroquinolone antibiotic (fourth-generation)","quality_score":57,"revenue":null,"mechanism":"Fourth-generation fluoroquinolone with the broadest spectrum, covering gram-positive, gram-negative, anaerobic, and atypical organisms."},{"drug_id":"sulfafurazole","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azo Gantrisin","generic_name":"sulfafurazole","company_name":"Alra","drug_phase":"marketed","molecular_target":"Endothelin-1 receptor","drug_class":"Sulfonamide Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"trimethoprim","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trimethoprim","generic_name":"TRIMETHOPRIM","company_name":"Dr Reddys Labs Sa","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"Sulfonamide Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefaclor","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceclor","generic_name":"CEFACLOR","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"cefaclor","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"mandelic-acid","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amygdalic Acid","generic_name":"mandelic acid","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"mandelic acid","quality_score":null,"revenue":null,"mechanism":"Amygdalic Acid works by inhibiting bacterial growth and replication in the urinary tract."},{"drug_id":"amphotericin-b","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"amphotericin-b","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"sulbactam","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"SULBACTAM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine beta-lactamase-like protein LACTB, mitochondrial","drug_class":"beta Lactamase Inhibitor","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"metronidazole","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metro I.V. In Plastic Container","generic_name":"METRONIDAZOLE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"demeclocycline","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Demethylchlortetracycline","generic_name":"DEMECLOCYCLINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor beta","drug_class":"Tetracycline-class Antimicrobial","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"cefepime-hydrochloride","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maxipime","generic_name":"Cefepime Hydrochloride","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Bacterial cell wall peptidoglycan","drug_class":"Cephalosporin","quality_score":64,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug that inhibits bacterial cell wall synthesis."},{"drug_id":"piperacillin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pipracil","generic_name":"PIPERACILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"piperacillin","quality_score":10,"revenue":null,"mechanism":"Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death."},{"drug_id":"piperacillin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pipracil","generic_name":"PIPERACILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"piperacillin","quality_score":10,"revenue":null,"mechanism":"Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death."},{"drug_id":"amoxicillin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amoxil","generic_name":"amoxicillin","company_name":"Generic (originally Beecham/GSK)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"Aminopenicillin (Beta-lactam antibiotic)","quality_score":56,"revenue":null,"mechanism":"Broad-spectrum aminopenicillin that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins."},{"drug_id":"cefepim","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cefepim","company_name":"University Hospital Tuebingen","drug_phase":"discontinued","molecular_target":"Bacterial penicillin-binding protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"acetohydroxamic-acid","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lithostat","generic_name":"ACETOHYDROXAMIC ACID","company_name":"Mission Pharma","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Urease Inhibitor [EPC]","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Infectious diarrheal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"tygacil","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tygacil","generic_name":"Tigecycline","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bacterial protein synthesis","drug_class":"Tetracycline","quality_score":10,"revenue":null,"mechanism":"Tigecycline is a tetracycline class antibacterial agent."},{"drug_id":"cefamandole","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefadole","generic_name":"CEFAMANDOLE","company_name":"","drug_phase":"phase_2","molecular_target":"Solute carrier family 15 member 1","drug_class":"cefamandole","quality_score":null,"revenue":null,"mechanism":"Cefadole works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"cefamandole","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefadole","generic_name":"CEFAMANDOLE","company_name":"","drug_phase":"phase_2","molecular_target":"Solute carrier family 15 member 1","drug_class":"cefamandole","quality_score":null,"revenue":null,"mechanism":"Cefadole works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"alatrofloxacin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ALATROFLOXACIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"alatrofloxacin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"alatrofloxacin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ALATROFLOXACIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"alatrofloxacin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelox","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avelox","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"meclocycline","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Meclan","generic_name":"MECLOCYCLINE","company_name":"Johnson And Johnson","drug_phase":"marketed","molecular_target":"","drug_class":"meclocycline","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"cyclacillin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ciclacillin","generic_name":"CYCLACILLIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"cyclacillin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"neomycin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"NEOMYCIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 1","drug_class":"Aminoglycoside Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"sitafloxacin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gracevit","generic_name":"SITAFLOXACIN","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"","drug_class":"sitafloxacin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bacampicillin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carampicillin","generic_name":"BACAMPICILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"bacampicillin","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"prulifloxacin","indication_name":"Lower urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PRULIFLOXACIN","company_name":"","drug_phase":"phase_3","molecular_target":"","drug_class":"prulifloxacin","quality_score":0,"revenue":null,"mechanism":"Prulifloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, disrupting bacterial DNA replication."},{"drug_id":"nifurtoinol","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Urfadine","generic_name":"NIFURTOINOL","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"nifurtoinol","quality_score":null,"revenue":null,"mechanism":"Urfadine works by inhibiting the growth and replication of bacteria in the urinary tract."},{"drug_id":"ceftriaxon","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxon","company_name":"Centre Hospitalier Universitaire Vaudois","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"avibactam","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avycaz","generic_name":"AVIBACTAM","company_name":"Cerexa Inc","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor [EPC]","quality_score":54,"revenue":null,"mechanism":"EMBLAVEO is an antibacterial drug."},{"drug_id":"merrem","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Merrem","company_name":"National Institutes of Health Clinical Center (CC)","drug_phase":"marketed","molecular_target":"Beta-lactamase, Beta-lactamase NDM-1, Beta-lactamase class B VIM-2","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"aztreonam","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azactam","generic_name":"AZTREONAM","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Monobactam Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Aztreonam inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"aztreonam","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azactam","generic_name":"AZTREONAM","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Monobactam Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Aztreonam inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"lincomycin","indication_name":"Staphylococcal infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lincocin","generic_name":"LINCOMYCIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"lincomycin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"lincomycin","indication_name":"Streptococcal infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lincocin","generic_name":"LINCOMYCIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"lincomycin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"methenamine","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hiprex","generic_name":"METHENAMINE","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"methenamine","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"lincomycin","indication_name":"Pneumococcal infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lincocin","generic_name":"LINCOMYCIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"lincomycin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ertapenem","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Invanz","generic_name":"ERTAPENEM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Penem Antibacterial","quality_score":70,"revenue":null,"mechanism":"Invanz works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"polymyxin-b","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"POLYMYXIN B","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Polymyxin-class Antibacterial","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"imipenem","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Primaxin","generic_name":"IMIPENEM","company_name":"Merck Sharp & Dohme B.V.","drug_phase":"marketed","molecular_target":"","drug_class":"imipenem","quality_score":70,"revenue":null,"mechanism":"Primaxin works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"ceftolozane","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zerbaxa","generic_name":"CEFTOLOZANE","company_name":"Cubist Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":"Zerbaxa works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"ceftolozane","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zerbaxa","generic_name":"CEFTOLOZANE","company_name":"Cubist Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":"Zerbaxa works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"amikacin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"ceftazidime","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"cefoxitin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"meropenem","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Merrem","generic_name":"Meropenem","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"meropenem","quality_score":10,"revenue":null,"mechanism":"Meropenem works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"cefonicid","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Monocid","generic_name":"CEFONICID","company_name":"","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"cefonicid","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cefadroxil","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefadrox","generic_name":"CEFADROXIL","company_name":"","drug_phase":"marketed","molecular_target":"Solute carrier family 15 member 1","drug_class":"cefadroxil","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefotetan","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefotan","generic_name":"CEFOTETAN","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Cephalosporin Antibacterial [EPC]","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"cilastatin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Primaxin","generic_name":"CILASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dipeptidase 1","drug_class":"Renal Dehydropeptidase Inhibitor","quality_score":65,"revenue":null,"mechanism":"Primaxin works by inhibiting the action of dehydropeptidase, an enzyme that breaks down certain antibiotics, thereby protecting them from degradation and allowing them to reach effective concentrations in the body."},{"drug_id":"azlocillin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AZLOCILLIN","company_name":"Bayer Pharmaceuticals Corp","drug_phase":"marketed","molecular_target":"","drug_class":"azlocillin","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"relebactam","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Recarbrio","generic_name":"RELEBACTAM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Renal Dehydropeptidase Inhibitor [EPC]","quality_score":34,"revenue":null,"mechanism":"Recarbrio works by inhibiting the beta-lactamase enzymes produced by certain bacteria, allowing carbapenem antibiotics to effectively target and kill the bacteria."},{"drug_id":"relebactam","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Recarbrio","generic_name":"RELEBACTAM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Renal Dehydropeptidase Inhibitor [EPC]","quality_score":34,"revenue":null,"mechanism":"Recarbrio works by inhibiting the beta-lactamase enzymes produced by certain bacteria, allowing carbapenem antibiotics to effectively target and kill the bacteria."},{"drug_id":"cefalotin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cephalotin","generic_name":"cefalotin","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 8","drug_class":"cefalotin","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"benzathine-benzylpenicillin","indication_name":"Streptococcal infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bicillin C-R","generic_name":"benzathine benzylpenicillin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"benzathine benzylpenicillin","quality_score":60,"revenue":null,"mechanism":"Bicillin C-R works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"ticarcillin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TICARCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"enoxacin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enoksetin","generic_name":"ENOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"RISC-loading complex subunit TARBP2","drug_class":"enoxacin","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TICARCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin-disodium","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ticarcillin","generic_name":"TICARCILLIN DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin-disodium","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ticarcillin","generic_name":"TICARCILLIN DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"kanamycin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kanacin","generic_name":"KANAMYCIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Gap junction beta-2 protein","drug_class":"Aminoglycoside Antibacterial","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"kanamycin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kanacin","generic_name":"KANAMYCIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Gap junction beta-2 protein","drug_class":"Aminoglycoside Antibacterial","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"clavulanic-acid","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Augmentin 250","generic_name":"CLAVULANIC ACID","company_name":"Dr Reddys Labs Inc","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"tazicef","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"Ceftazidime","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"Bacterial cell wall","drug_class":"Third-generation cephalosporin","quality_score":10,"revenue":null,"mechanism":"Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance."},{"drug_id":"norfloxacin","indication_name":"Infectious diarrheal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Infectious diarrheal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ceftizoxime","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epocelin","generic_name":"CEFTIZOXIME","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ceftizoxime","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epocelin","generic_name":"CEFTIZOXIME","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"cefmetazole","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zefazone","generic_name":"CEFMETAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"Insulin-degrading enzyme","drug_class":"cefmetazole","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"cefmetazole","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zefazone","generic_name":"CEFMETAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"Insulin-degrading enzyme","drug_class":"cefmetazole","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"carbenicillin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Carboxybenzylpenicillin","generic_name":"CARBENICILLIN","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"minocycline","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Minocycline Hydrochloride","generic_name":"MINOCYCLINE","company_name":"Rempex","drug_phase":"marketed","molecular_target":"","drug_class":"Tetracycline-class Drug","quality_score":75,"revenue":null,"mechanism":"MINOCYCLINE works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"fosfomycin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Monurol","generic_name":"FOSFOMYCIN","company_name":"Zambon Spa","drug_phase":"marketed","molecular_target":"","drug_class":"fosfomycin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Infectious diarrheal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"cinoxacin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cinobac","generic_name":"CINOXACIN","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"cinoxacin","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"cefixime","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Suprax","generic_name":"CEFIXIME","company_name":"","drug_phase":"marketed","molecular_target":"1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1","drug_class":"cefixime","quality_score":10,"revenue":null,"mechanism":"Suprax works by inhibiting the bacterial enzyme 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1, disrupting bacterial cell wall synthesis."},{"drug_id":"ceftriaxone","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rocephin","generic_name":"ceftriaxone","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"Cephalosporin antibiotic (third-generation)","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"oxacillin","indication_name":"Staphylococcal infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bactocill In Plastic Container","generic_name":"OXACILLIN","company_name":"Apothecon","drug_phase":"marketed","molecular_target":"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"enoxa","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENOXA®","company_name":"Les Laboratoires des Médicaments Stériles","drug_phase":"marketed","molecular_target":"RISC-loading complex subunit TARBP2, V-type proton ATPase subunit B, brain isoform, DNA gyrase","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Enoxa is a small molecule drug, but its exact mechanism of action is unknown."},{"drug_id":"cephradin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cephradin","company_name":"Sohag University","drug_phase":"phase_2","molecular_target":"Matrix metalloproteinase-9, Somatostatin receptor type 4, Bacterial penicillin-binding protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"penicillin","indication_name":"Streptococcal infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"penicillin","company_name":"Karlstad University","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ceftazidim","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftazidim","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"metronidazol","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Metronidazol","company_name":"University of Oslo","drug_phase":"marketed","molecular_target":"Thioredoxin reductase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Infectious diarrheal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amoxicilli","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxicilli","company_name":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mezlocillin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MEZLOCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"Interleukin-8","drug_class":"mezlocillin","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"minocyclin","indication_name":"Urinary tract infectious disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Minocyclin","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":126,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05013944","title":"AnovaOS Network Powered Patient Registry","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Anova Enterprises, Inc","has_results":false},{"nct_id":"NCT07047768","title":"Artificial Intelligence for Respiratory Infections SEverity Prediction","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT05780099","title":"Prospective Observational Study to Characterize Patients Treated at Internal Medicine Clinics","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT06159270","title":"Infectious Prospective Collection for Biological Analysis","phase":"","overall_status":"UNKNOWN","enrollment_count":22870,"lead_sponsor_name":"CerbaXpert","has_results":false},{"nct_id":"NCT07071701","title":"A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target Population","phase":"","overall_status":"COMPLETED","enrollment_count":19267,"lead_sponsor_name":"Sinovac Biotech Co., Ltd","has_results":false},{"nct_id":"NCT06431217","title":"Group B Strep Correlates of Protection Study","phase":"","overall_status":"COMPLETED","enrollment_count":17842,"lead_sponsor_name":"University of Witwatersrand, South Africa","has_results":false},{"nct_id":"NCT06357650","title":"Collaborative Open Research Initiative Study (CORIS-1)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Chisquares Incorporated","has_results":false},{"nct_id":"NCT06879184","title":"Cohort of the Specialist Network Infectious Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Goethe University","has_results":false},{"nct_id":"NCT02111564","title":"A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":12024,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT06492187","title":"Triage Survey for Infectious Disease Eligibility","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brooklyn Clinical Research","has_results":false},{"nct_id":"NCT05889806","title":"AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens)","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"Audubon Bioscience","has_results":false},{"nct_id":"NCT04031651","title":"Key Specialized Monitoring of Clinical Safety of Pudilan Xiaoyan Oral Liquid in the Real World","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"China Academy of Chinese Medical Sciences","has_results":false},{"nct_id":"NCT03848962","title":"Collection and Distribution of Biospecimens for Novel Research Uses","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"iSpecimen Inc","has_results":false},{"nct_id":"NCT04816318","title":"Policy Responses Against the COVID-19 Pandemic in Latin America","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"University of Chile","has_results":false},{"nct_id":"NCT05350995","title":"Evaluation of Antibiotherapy Prescribed for Outpatients From Emergency Departments","phase":"","overall_status":"UNKNOWN","enrollment_count":9600,"lead_sponsor_name":"Henri Mondor University Hospital","has_results":false},{"nct_id":"NCT04474028","title":"An Epidemiological Investigation on the Correct Wearing of Face Mask","phase":"","overall_status":"COMPLETED","enrollment_count":6000,"lead_sponsor_name":"Fuwai Yunnan Cardiovascular Hospital","has_results":false},{"nct_id":"NCT04497675","title":"An Epidemiological Investigation on Correct Wearing of Mask by Direct Spray Test","phase":"","overall_status":"COMPLETED","enrollment_count":6000,"lead_sponsor_name":"Fuwai Yunnan Cardiovascular Hospital","has_results":false},{"nct_id":"NCT04497753","title":"An Epidemiological Investigation on Correct Wearing of Mask by Hood Test","phase":"","overall_status":"COMPLETED","enrollment_count":6000,"lead_sponsor_name":"Fuwai Yunnan Cardiovascular Hospital","has_results":false},{"nct_id":"NCT05244356","title":"Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation","phase":"NA","overall_status":"COMPLETED","enrollment_count":5784,"lead_sponsor_name":"Clinical Research Centre, Malaysia","has_results":false},{"nct_id":"NCT06422338","title":"A Rapid Triage Test to Improve Risk-stratification of Febrile Children (EChiLiBRiST, Clinical Trial 1, Outpatients)","phase":"NA","overall_status":"RECRUITING","enrollment_count":5212,"lead_sponsor_name":"Barcelona Institute for Global Health","has_results":false},{"nct_id":"NCT05766826","title":"Coupons for Safe Water Project","phase":"NA","overall_status":"RECRUITING","enrollment_count":3468,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT06617715","title":"Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":3080,"lead_sponsor_name":"Sinovac Life Sciences Co., Ltd.","has_results":false},{"nct_id":"NCT03329768","title":"Evaluation of Medical Device","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT03228095","title":"Volatiles in Breath and Headspace Analysis - Diagnostic Markers","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"University of Latvia","has_results":false},{"nct_id":"NCT04842071","title":"18F-sodium Fluoride (NaF) PET to Replace Bone Scintigraphy: Safety and Efficacy Assessment","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","has_results":false},{"nct_id":"NCT00001281","title":"Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV","phase":"","overall_status":"RECRUITING","enrollment_count":2419,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT06426147","title":"L-citrulline to Improve Adverse Outcomes in Admitted Children (EChiLiBRiST, Clinical Trial 2, Inpatients)","phase":"NA","overall_status":"RECRUITING","enrollment_count":2200,"lead_sponsor_name":"Barcelona Institute for Global Health","has_results":false},{"nct_id":"NCT03489330","title":"Antibiotic Outbreak, Risk Factors for Never Event, Prediction of Inappropriate Use","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Midwestern University","has_results":false},{"nct_id":"NCT03737669","title":"Mirasol Evaluation of Reduction in Infections Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT04364503","title":"Compliant Analysis of Patient Samples and Data","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Sequenom, Inc.","has_results":false},{"nct_id":"NCT06553911","title":"Exploring the Application Efficacy of Artificial Intelligence (AI) Diagnostic Tools in Medical Imaging (MI) of Respiratory(R) Infectious (I) Disease (D)","phase":"NA","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT06102070","title":"Genetic Susceptibility to Severe Infections","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT03333863","title":"Bacterial and Antimicrobial Susceptibility Profile and the Prevalence of Different Sites of Infection(BASPP)","phase":"","overall_status":"COMPLETED","enrollment_count":1889,"lead_sponsor_name":"Shengjing Hospital","has_results":false},{"nct_id":"NCT04353141","title":"International Lung UltraSound Analysis (ILUSA) Study","phase":"","overall_status":"UNKNOWN","enrollment_count":1850,"lead_sponsor_name":"KU Leuven","has_results":false},{"nct_id":"NCT03058484","title":"Community Health Workers and Prevention of Mother-to-Child HIV Transmission in Tanzania","phase":"NA","overall_status":"COMPLETED","enrollment_count":1830,"lead_sponsor_name":"University of California, Berkeley","has_results":false},{"nct_id":"NCT06574776","title":"Prevalence and Associated Mortality of Infections by Multidrug-Resistant Organisms in Adults Intensive Care Units","phase":"","overall_status":"COMPLETED","enrollment_count":1799,"lead_sponsor_name":"Hospital Italiano de Buenos Aires","has_results":false},{"nct_id":"NCT07069400","title":"An International Observational Study of Adults With Acute Infection","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"University of Minnesota","has_results":false},{"nct_id":"NCT03232242","title":"Application of NGS Technique in Precise Diagnosis of Infectious Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT04848883","title":"Infectious Diseases Experts as Part of the Antibiotic Stewardship Team in Primary Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":1389,"lead_sponsor_name":"Institut d'Investigació Biomèdica de Bellvitge","has_results":false},{"nct_id":"NCT04001309","title":"Antimicrobial Stewardship Interventions in a Hospital Setting","phase":"NA","overall_status":"COMPLETED","enrollment_count":1312,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT05195866","title":"CRP for Respiratory Diagnosis in Kyrgyz Pediatric Practice","phase":"NA","overall_status":"COMPLETED","enrollment_count":1204,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03996304","title":"Health and Early Life Microbiota","phase":"","overall_status":"UNKNOWN","enrollment_count":1055,"lead_sponsor_name":"University of Helsinki","has_results":false},{"nct_id":"NCT04320810","title":"Developing Metagenomic Approaches to Identify the Causes of Pediatric Infectious Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT06722131","title":"Biobank of Samples From Patients With Infectious Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT02669823","title":"Optimizing Sysmex Technology as an Innovative Tool to Differentiate Between Malaria (PALUdism) and BACterial Infections in a Malaria Endemic Region","phase":"","overall_status":"COMPLETED","enrollment_count":930,"lead_sponsor_name":"Sysmex Europe GmbH","has_results":false},{"nct_id":"NCT03457688","title":"Effect of Prebiotic Fructans to Reduce Number of Febrile Infections in Children","phase":"NA","overall_status":"COMPLETED","enrollment_count":850,"lead_sponsor_name":"Beneo-Institute","has_results":false},{"nct_id":"NCT07411729","title":"Establishment of a Biobank for the Evaluation of Rapid Diagnostic Solutions","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03912246","title":"Collection of Human Biological Samples for the Development and Validation of New Methods of Diagnosis and for the Realization of Expertises Diagnostics in the Field of Infectious Diseases and Tropical","phase":"NA","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Institut Pasteur","has_results":false},{"nct_id":"NCT04977739","title":"Research on the Application and Mechanism of New Biological Probes in Biomedicine","phase":"","overall_status":"COMPLETED","enrollment_count":737,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT05286879","title":"Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations","phase":"NA","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Yale University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}